Relievant gets FDA OK for expanded back-pain-device trial

06/4/2013 | MassDevice.com (Boston)

The FDA has granted Relievant Medsystems investigational device exemption to conduct a larger clinical study of its Intracept basivertebral nerve ablation device. The 200-participant trial will be expanded to include 20 U.S. clinical sites, where the device will be tested for treating recurrent low back pain.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ